Last reviewed · How we verify

Coly-Mycin M — Competitive Intelligence Brief

Coly-Mycin M (COLISTIMETHATE SODIUM) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Polymyxin-class Antibacterial. Area: Metabolic.

marketed Polymyxin-class Antibacterial Metabolic Live · refreshed every 30 min

Target snapshot

Coly-Mycin M (COLISTIMETHATE SODIUM) — Ph Health.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Coly-Mycin M TARGET COLISTIMETHATE SODIUM Ph Health marketed Polymyxin-class Antibacterial 1970-01-01
Cortisporin POLYMYXIN B Pfizer marketed Polymyxin-class Antibacterial 1957-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Polymyxin-class Antibacterial class)

  1. Pfizer · 1 drug in this class
  2. Ph Health · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Coly-Mycin M — Competitive Intelligence Brief. https://druglandscape.com/ci/colistimethate-sodium. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing